Antisecretory agents for prevention of post-ERCP pancreatitis: Rationale for use and clinical results

Journal of the Pancreas

Volumn 4, Issue 1, 2003, Pages 33-40

  Poon, Ronnie Tung Ping ^a   Fan, Sheung Tat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cholangiopancreatography, endoscopic retrograde; Endoscopic sphincterotomy; Octreotide; Somatostatin

Indexed keywords

AMYLASE; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; STOMACH SECRETION INHIBITOR; DRUG DERIVATIVE; SOMATOSTATIN;

ACUTE PANCREATITIS; AMYLASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; HIGH RISK PATIENT; HUMAN; INCIDENCE; ODDI SPHINCTER; PATHOGENESIS; POSTOPERATIVE COMPLICATION; ANIMAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; HUMANS; OCTREOTIDE; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 0037267964     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sherman S, Lehman GA. ERCP- and endoscopic sphincterotomy-induced pancreatitis. Pancreas 1991; 6:350-67. [AN 91319689]
2. Freeman M, Nelson D, Sherman S, Haber G, Herman M, Dorsher P, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909-18. [AN 96365275]
3. Sherman S, Hawes RH, Rathgaber SW, Uzer MF, Smith MT, Khusro QE, et al. Post-ERCP pancreatitis: randomized, prospective study comparing a low and high-osmolarity contrast agent. Gastrointest Endosc 1994; 40:422-7. [AN 95011329]
4. Johnson GK, Geenen JE, Bedford RA, Johanson J, Cass O, Sherman S, et al. A comparison of nonionic versus ionic contrast media: results of a prospective multicenter study-Midwest Pancreaticobiliary Study Group. Gastrointest Endosc 1995; 42:312-6. [AN 96121321]
5. Gottlieb K, Sherman S, Pezzi J, Esber E, Lehman GA. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996; 91:1553-7. [AN 96322170]
6. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1-10. [AN 98347799]
7. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscpic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37:383-93. [AN 91301427]
8. Testoni PA, Bagnolo F. Pain at 24 hours associated with amylase levels greater than 5 times the upper normal limit as the most reliable indicator of post-ERCP pancreatitis. Gastrointest Endosc 2001; 53:33-9. [AN 21067928]
9. Sherman S, Ruffolo TA, Hawes RH, Lehman GA. Complications of endoscopic sphincterotomy. A prospective series with emphasis on the increased risk associated with sphincter of Oddi dysfunction and nondilated bile ducts. Gastroenterology 1991; 101:1068-75. [AN 91365172]
10. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54:425-34. [AN 21460528]
11. Vandervoort J, Soetikno RM, Tham TC, Wong RC, Ferrari AP Jr, Montes H, et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56:652-6. [AN 22283811]
12. Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol 1998; Suppl 228:115-21. [AN 99083010]
13. Harris AG. Octreotide in the treatment of disorders of the gastrointestinal tract. Drug Invest 1992; 4 (Suppl3):1-54.
14. Glasbrenner B, Adler G. Pathophysiology of acute pancreatitis. Hepatogastroenterology 1993; 40:517-21. [AN 94164589]
15. Lankisch PG, Koop H, Winckler K, Folsch UR, Creutzfeldt W. Somatostatin therapy of acute experimental pancreatitis. Gut 1977; 18:713-6. [AN 78107911]
16. Baxter JN, Jenkins SA, Day DW, Roberts NB, Cowell DC, Mackie CR, et al. Effects of somatostatin and a long-acting somatostatin analogue on the prevention and treatment of experimentally induced acute pancreatitis in the rat. Br J Surg 1985; 72:382-5. [AN 85200606]
17. Saluja AK, Steer ML. Pathophysiology of acute pancreatitis: role of cytokines and other mediators of inflammation. Digestion 1999; 60:27-33. [AN 99152095]
18. Matucci-Cerinic M, Borrelli F, Generini S, Cantelmo A, Marcucci I, Martelli F, et al. Somatostatin-induced modulation of inflammation in experimental arthritis. Arthritis Rheum 1995; 38:1687-93. [AN 96062444]
19. Karalis K, Mastorakos G, Chrousos GP, Tolis G. Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 1994; 93:2000-6. [AN 94237964]
20. Yuan Y, Gong Z, Lou K, Tu S, Di Z, Xu J. Effects and mechanisms of somatostatin analogs on apoptosis of pancreatic acinar cells in acute pancreatitis in mice. J Gastroenterol Hepatol 2001; 16:683-8. [AN 21316685]
21. Deviere J, Le Moine O, van Laethem JL, Eisendrath P, Ghilain A, Severs N, Cohard M. Interleukin-10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001; 120:498-505. [AN 21100083]
22. Papp M. Pancreatic cytoprotection. New approaches. Acta Physiol Hung 1992; 80:399-406. [AN 94262489]
23. Ahrendt SA, McGuire GE, Lillemore KD, Trias M, Kaloo A, Pitt HA. Somatostatin inhibits sphincter of Oddi motility [abstract]. Gastroenterology 1990; 98:A242.
24. Lai KH, Lo GH, Cheng JS, Fu MT, Wang EM, Chan HH, et al. Effect of somatostatin on the sphincter of Oddi in patients with acute non-biliary pancreatitis. Gut 2001; 49:843-6. [AN 21566131]
25. Binmoeller KF, Dumas R, Harris AG, Delmont JP. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992; 37:773-7. [AN 92224786]
26. Di Francesco V, Angelini G, Bovo P, Casarini MB, Filippini M, Vaona B, et al. Effect of octreotide on sphincter of Oddi motility in patients with acute recurrent pancreatitis: a manometric study. Dig Dis Sci 1996; 41:2392-6. [AN 97148645]
27. Jenkins SA, Berein A. Review article: the relative effectiveness of somatostatin and octreotide therapy in pancreatic disease. Aliment Pharmacol Ther 1995; 9:349-61. [AN 96063782]
28. Borsch G, Bergbauer M, Nebel W, Sabin G. Der einflu von somatostatin auf die amylasepiegel und pankreatistrate nach ERCP. [Effect of somatostatin on amylase level and pancreatitis rate following ERCP] Med Welt 1984; 35:109-12. [AN 84141123]
29. Cicero GF, Lauger R, Sahel J, Manganaro M, Sarles H. Effect of somatostatin on clinical, biochemical and morphological changes following ERCP. Ital J Gastroenterol 1985; 17:265-8.
30. Tyden G, Nyberg B, Sonnefeld T, Thulin L. Effect of somatostatin on hyperamylasemia following endoscopic pancreatography. Acta Chir Scand 1986; 530:43-5. [AN 86264305]
31. Bordas JM, Toledo V, Mondelo F, Rodes J. Prevention of pancreatic reactions by bolus somatostatin administration in patients undergoing endoscopic retrograde cholangio-pancreatography and endoscopic sphincterotomy. Hormone Res 1988; 29:106-8. [AN 88297533]
32. Bordas JM, Toledo-Pimentel V, Llach J, Elena M, Mondelo F, Gines A, et al. Effects of bolus somatostatin in preventing pancreatitis after endoscopic pancreatography: results of a randomized study. Gastrointest Endosc 1998; 47:230-4. [AN 98199942]
33. Saari A, Kivilaakso E, Schroder . The influence of somatostatin on pancreatic irritation after pancreatography. An experimental and clinical study. Surg Res Comm 1988; 2:271-8.
34. Testoni PA, Masci E, Bagnolo F, Tittobello A. Endoscopic papillo-sphincterotomy: prevention of pancreatic reaction by somatostatin. Ital J Gastroenterol 1988; 20:70-3.
35. Persson B, Slezak P, Efendic S, Haggmark A. Can somatostatin prevent injection pancreatitis after ERCP? Hepatogastroenterology 1992; 39:259-61. [AN 92371924]
36. Guelrud M, Mendoza S, Viera L, Gelrud D. Somatostatin prevents acute pancreatitis after pancreatic duct sphincter hydrostatic balloon dilation in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc 1991; 37:44-7. [AN 91169195]
37. Poon RT, Yeung C, Lo CM, Yuen WK, Liu CL, Fan ST. Prophylactic effect of somatostatin on post-ERCP pancreatitis: a randomized controlled trial. Gastrointest Endosc 1999; 49:593-8. [AN 99246296]
38. Andruilli A, Leandro G, Niro G, Mangia A, Festa V, Gambassi G, et al. Pharmacological treatment can prevent pancreatic injury after ERCP: a meta-analysis. Gastrointest Endosc 2000; 51:1-7. [AN 20092786]
39. Andriulli A, Clemente R, Solmi L, Terruzzi V, Suriani R, Sigillito A, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebocontrolled, randomized clinical trial. Gastrointest Endosc 2002; 56:488-95. [AN 22233811]
40. Tulassay Z, Papp J. The effect of long-acting somatostatin analogue on enzyme changes after endoscopic pancreatography. Gastrointest Endosc 1991; 37:48-50. [AN 91169196]
41. Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992; 87:1561-6. [AN 93071823]
42. Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992; 33:1129-33. [AN 93013162]
43. Arcidiacono R, Gambitta P, Rossi A, Grosso C, Bini M, Zanasi G. The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy. Endoscopy 1994; 26:715-8. [AN 95228572]
44. Arvanitidis D, Hatzipanayiotis J, Koutsounopoulos G, Frangou E. The effect of octreotide on the prevention of acute pancreatitis and hyperamylasemia after diagnostic and therapeutic ERCP. Hepatogastroenterology 1998; 45:248-52. [AN 98157607]
45. Testoni PA, Lella F, Bagnolo F, Buizza M, Colombo E. Controlled trial of different dosages of octreotide in the prevention of hyperamylasemia induced by endoscopic papillosphincterotomy. Ital J Gastroenterol 1994; 26:431-6. [AN 95322622]
46. Testoni PA, Lella F, Bagnolo F, Caporuscio S, Cattani L, Colombo E, et al. Long term prophylactic administration of octreotide reduces the rise in serum amylase after endoscopic procedures on Vater's papilla. Pancreas 1996; 13:61-5. [AN 96377495]
47. Testoni PA, Bagnolo F, Andriulli A, Bernasconi G, Crotta S, Lella F, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001; 15:965-72. [AN 21314850]
48. Messman H, Vogt W, Holstege A, Lock G, Heinisch A, von Fürstenberg A, et al. Post-ERCP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut 1997; 40:80-5. [AN 97300559]